Effect of combination of calcium antagonist, azelnidipine, and AT 1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice

Journal of Hypertension

Volumn 23, Issue 7, 2005, Pages 1383-1389

  Suzuki, Jun ^a   Iwai, Masaru ^a   Li, Zhen ^a   Li, Jian Mei ^a   Min, Li Juan ^a   Ide, Ayumi ^a   Yoshii, Toyofumi ^a   Oshita, Akira ^a   Mogi, Masaki ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AT1 receptor blocker; Atherosclerosis; Calcium antagonist; Oxidative stress

Indexed keywords

AZELNIDIPINE; CHOLESTEROL; OLMESARTAN; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; MONOTHERAPY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

EID: 21644472752     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000173521.91104.5f     Document Type: Article

References (24)

1. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999; 99:2027-2033.
2. Azumi H, Inoue N, Ohashi Y, Terashima M, Mori T, Fujita H, et al. Superoxide generation in directional coronary atherectomy specimens of patients with angina pectoris: important role of NAD(P)H oxidase. Arterioscter Thromb Vasc Biol 2002; 22:1838-1844.
3. Steinberg D, Lewis A. Oxidative modification of LDL and atherogenesis. Circulation 1997; 95:1062-1071.
4. Thomas SR, Chen K, Keaney JF Jr. Oxidative stress and endothelial nitric oxide bioactivity. Antiox Redox Signal 2003; 5:181-194.
5. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin Ii stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74:1141-1148.
6. de Gasparo M, Catt KJ, Inagami T, Wright JW, Linger T. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52:415-472.
7. Henry PD, Bentley KI. Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest 1981; 68:1366-1369.
8. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet 1990; 335:1109-1113.
9. Eguchi S, Inagami T. Signal transduction of angiotensin II type 1 receptor through receptor tyrosine kinase. Regul Pept 2000; 91:13-20.
10. Jinno T, Iwai M, Li Z, Li JM, Liu HW, Cui TX, et al. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension 2004; 43:263-269.
11. Ozaki M, Kawashima S, Yamashita T, Hirase T, Namiki M, Inoue N, et al. Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J Clin Invest 2002; 110:331-340.
12. Horiuchi M, Hayashida W, Akishita M, Tamura K, Daviet L, Lehtonen JY, et al. Stimulation of different subtypes of angiotensin II receptors, AT1 and AT2 receptors, regulates STAT activation by negative crosstalk. Circ Res 1999; 84:876-882.
13. Szocs K, Lassegue B, Sorescu D, Hilenski LL, Valppu L, Couse TL, et al. Upregulation of nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol 2002; 22:21-27.
14. Iwai M, Liu HW, Chen R, Ide A, Okamoto S, Hata R, et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 2004; 110:843-848.
15. 2 in angiotensin II-induced vascular hypertrophy. Hypertension 1998; 32:488-495.
16. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258:468-471.
17. Candido R, Allen TJ, Lassila M, Cao Z, Thallas V, Cooper ME, et al. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 2004; 109:1536-1542.
18. Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997; 95:473-478.
19. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 1996; 271:23317-2321.
20. Barry-Lane PA, Patterson C, van der Merwe M, Hu Z, Holland SM, Yeh ET, et al. p47phox is required for atherosclerotic lesion progression in apoE(-/-) mice. J Clin Invest 2001; 108:1513-1522.
21. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999; 13:2905-2927.
22. Stabile E, Zhou YF, Saji M, Castagna M, Shou M, Kinnaird TD, et al. Akt controls vascular smooth muscle cell proliferation in vitro and in vivo by delaying G1/S exit. Circ Res 2003; 93:1059-1065.
23. Seewald S, Seul C, Kettenhofen R, Bokemeyer D, Ko Y, Vetter H, et al. Role of mitogen-activated protein kinase in the angiotensin II-induced DNA synthesis in vascular smooth muscle cells. Hypertension 1998; 31:1151-1156.
24. Hirata A, Igarashi M, Yamaguchi H, Suwabe A, Daimon M, Kato T, et al. Nifedipine suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK-ERK pathway coupling with Pyk2. Br J Pharmacol 2000; 131:1521-1530.